Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Ontology highlight
ABSTRACT: Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.
Phase 2: Assessment of the objective response rate (ORR), measured by RECIST 1.1 criteria as assessed by blinded independent central review (BICR).
DISEASE(S): Carcinoma,Advanced Gastrointestinal (gi) Malignancies,Gastric Cancer,Colorectal Cancer,Carcinoma, Hepatocellular,Advanced Hepatocellular Carcinoma (hcc)in The Third Line Or Later Setting,Carcinoma Hepatocellular,Neoplasms,Hepatocellular Carcinoma
PROVIDER: 2163812 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA